The abstract is read at the publisher; the summary is JClub's.
In 29 patients with advanced cervical cancer, higher baseline frequencies of TOX+ TIGIT+ CD57+ TEMRA CD8+ T cells (CD45RA+CCR7-) are linked to better clinical benefit, PFS, and OS under durvalumab, tremelimumab, and metronomic vinorelbine.
- Why it matters: Immune biomarkers are needed to predict who benefits from combined anti-PD-L1, anti-CTLA-4, and chemotherapy, since response varies in pretreated metastatic disease.
- What they did: Baseline PBMCs from the MOVIE phase I/II trial were profiled by CyTOF using T-cell, NK-cell, and myeloid panels, followed by opt-SNE/UMAP, PhenoGraph, CITRUS, and an 11-algorithm machine-learning prediction model.
- The result: Using a 0.73% CD45+ cutoff, patients with increased TOX+ TIGIT+ CD57+ TEMRA CD8+ T cells had higher CBR (76% vs 25%, p=0.005), improved PFS (HR=0.35, p=0.013), and improved OS (HR=0.19, p=0.001), with OS benefit remaining after multivariate adjustment (HR=0.15, p<0.001).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.